Management of hepatocellular carcinoma: an update.
Bruix J, Sherman M, American Association for the Study of Liver Diseases. · 2011
Read Management of hepatocellular carcinoma: an update. by Bruix J, Sherman M, American Association for the Study of Liver Diseases. (2011) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/europmc-pmc3084991.txt.
Description
Bruix and Sherman summarized in 2011 the updated practice guidelines for liver cell cancer from the American liver disease association, replacing the 2005 version. New evidence had accumulated on who to watch, how to diagnose, and how to stage and treat this cancer, which usually grows on a scarred liver. The summary highlights only what changed.
Blood marker testing was dropped from surveillance because it misses too much and cries wolf too often, leaving ultrasound every six months as the standard. Diagnosis now rests on one good dynamic scan showing the classic pattern of bright uptake then washout, for the right patients. A common contrast ultrasound method was removed after false alarms in a related bile duct cancer. Biopsy reading was strengthened with a three stain panel. Risk thresholds for starting surveillance were refined for hepatitis B and C. The full guideline lives on the association website.
Catalog record
| CREATOR | Bruix J, Sherman M, American Association for the Study of Liver Diseases. |
|---|---|
| YEAR | 2011 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 9 KB |
| LICENSE | CC BY 4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |